Efficient methods for signal detection from correlated adverse events in clinical trials by Diao, G. et al.
Efficient methods for signal detection from correlated adverse
events in clinical trials
Guoqing Diao 1 Guanghan F. Liu2 Donglin Zeng 3 William Wang2 Xianming
Tan3 Joseph F. Heyse2 Joseph G. Ibrahim3
1Department of Statistics, George Mason
University, Fairfax, Virginia
2Merck & Co., Inc., North Wales,
Pennsylvania
3Department of Biostatistics, University
of North Carolina at Chapel Hill, Chapel
Hill, North Carolina
Correspondence
Guoqing Diao, Department of Statistics,
George Mason University, Fairfax, VA
Email: gdiao@gmu.edu
Abstract
It is an important and yet challenging task to identify true signals from many adverse
events that may be reported during the course of a clinical trial. One unique feature
of drug safety data from clinical trials, unlike data from post-marketing spontaneous
reporting, is that many types of adverse events are reported by only very few patients
leading to rare events. Due to the limited study size, the 𝑝-values of testing whether the
rate is higher in the treatment group across all types of adverse events are in general
not uniformly distributed under the null hypothesis that there is no difference between
the treatment group and the placebo group. A consequence is that typically fewer
than 100𝛼 percent of the hypotheses are rejected under the null at the nominal sig-
nificance level of 𝛼. The other challenge is multiplicity control. Adverse events from
the same body system may be correlated. There may also be correlations between
adverse events from different body systems. To tackle these challenging issues,
we develop Monte-Carlo-based methods for the signal identification from patient-
reported adverse events in clinical trials. The proposed methodologies account for the
rare events and arbitrary correlation structures among adverse events within and/or
between body systems. Extensive simulation studies demonstrate that the proposed
method can accurately control the family-wise error rate and is more powerful than
existing methods under many practical situations. Application to two real examples
is provided.
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1 INTRODUCTION
Assuring the safety of human drug products has been a key
component of the mission of the Food and Drug Adminis-
tration (FDA). Drug safety is typically studied and evaluated
in clinical trials. Across the clinical development program,
it is a continuous effort and mandatory to collect safety data
including patient-reported adverse events (AEs). For example,
serious cardiac AEs are closely monitored for investigative
diabetes drugs (Food and Drug Administration, 2008); or seri-
ous vaccine related AEs are monitored throughout the study
for vaccines (Mehrotra and Heyse, 2004a). Patient-reported
AEs are often grouped into different body systems (BSs) or
system organ classes (SOCs). Examples of common SOCs
include cardiac disorders, gastrointestinal disorders, infec-
tions and infestations, nervous systems, renal and urinary,
and respiratory systems, etc. The detailed SOC listing is
maintained by Medical Dictionary for Regulatory Activities
(MedDRA, 2018). An important task in drug safety analysis
is to identify true AEs from many possible AEs that may be
reported (Jiang and Snapinn, 2016; Wang et al., 2018).
To detect drug safety signals, two types of data arise in
practice: data from spontaneous reporting (SR) and data from
clinical trials. In spontaneous reporting, health professionals
or patients report suspected harm from a medicine to their
local or national drug administration. Such data are often
stored in some databases. For example, the Vaccine Adverse
Event Reporting System (VAERS), which is co-sponsored by
the FDA and the Centers for Disease Control and Preven-
tion (CDC), collects AEs that occur after the administration
of US licensed vaccines. The FDA Adverse Event Reporting
System (FAERS) is a database that contains AE reports, med-
ication error reports and product quality complaints resulting
in AEs that were submitted to FDA. Data from such databases
include many different drugs and many different types of AEs
across different SOCs. Various methods have been developed
for safety signal detection (or detection of drug-AE pairs)
using data from SR; for example, proportional reporting ratios
(Evans et al., 2001), reporting odds ratios (Rothman et al.,
2004), the likelihood ratio tests (Huang et al., 2014, 2011,
2013, 2017; Nam et al., 2017; Zhao et al., 2018), and Bayesian
methods (Bate et al., 1998; DuMouchel, 1999; DuMouchel
and Pregibon, 2001; Norén et al., 2006; Hu et al., 2015).
On the other hand, in clinical trials, patients are typically
randomly allocated to a treatment group and a placebo (con-
trol) group. During the course of the clinical trials, adverse
events will be reported to the investigators. The interest is to
know whether the risk of an AE is higher in the treatment
group than the placebo group. Classical statistical tests such
as Fisher’s exact test, Pearson’s chi-square test, and chi-square
test for comparison of event rates can be used to perform
hypothesis testing for each possible AE (Miettinen and Nur-
minen, 1985). More recently, Bayesian hierarchical mixture
models and their variations have been developed for detect-
ing safety signals in clinical trials (Berry and Berry, 2004;
Xia et al., 2011, DuMouchel, 2012; Price et al., 2014; Odani
et al., 2017).
An important issue in drug safety signal detection is mul-
tiplicity. Failing to adjust for multiple testing can yield an
abundance of false positive results. The Bonferroni correc-
tion can control the family-wise error rate (FWER); however
this procedure assumes that all AE terms are mutually inde-
pendent and therefore can be overly conservative. Benjamini
and Hochberg (1995) introduced the concept of false discov-
ery rate (FDR) and the so-called BH procedure to control
FDR based on sequential Bonferroni-type adjustment. Sev-
eral variations of FDR have been proposed in literature, see
for example, pFDR (Storey, 2002) and DFDR (Mehrotra and
Heyse, 2004b; Mehrotra and Adewale, 2012). FDR-based
methods for drug safety signal detection have been discussed
in Ahmed et al. (2010, 2012). Huang et al. (2011) proposed
likelihood ratio test methods to handle the multiplicity issue
using gate keep procedures and Monte Carlo simulations.
Chen et al. (2015) compared the performance of various meth-
ods for SR data and clinical trial data through simulation
studies.
Essentially none of the above procedures accounts for pos-
sible correlations among the risks of AEs within the same
SOC or across different SOCs. To account for such corre-
lations, one can incorporate correlations by using random
effects without specifying the correlation structure; however,
inference of the unknown parameters under the random effects
model involves high-dimensional integrals and the computa-
tion is intensive especially when the total number of AE terms
is large. An alternative approach is the permutation resam-
pling approach by shuffling the treatment assignments. How-
ever, the permutation approach is computationally demand-
ing since repeated analysis over the permuted data sets is
needed. The computation can be infeasible when the num-
ber of hypotheses is large and the analysis of each data set
is time-consuming. Furthermore, the permutation approach
requires complete exchangeability under the null hypothesis,
which may not be satisfied in practice.
Furthermore, unlike data from SR, in clinical trials for
many AE terms only very few patients experience the events,
leading to rare events. As is shown in the Web Appendix A,
due to the limited study size, the 𝑝-values of testing whether
the rate is higher in the treatment group across all AE terms are
in general not uniformly distributed between 0 and 1 under the
null hypothesis. Particularly, with rare events, the distribution
of the 𝑝-values under the null hypothesis is highly left skewed.
Consequently, fewer than 100𝛼 percent of the hypotheses are
rejected under the null at the nominal significance level of
𝛼 and methods using large sample approximations may not
perform well.
Recently, in the context of genome-wise associate stud-
ies (GWAS), Diao and Vidyashankar (2013) and Diao et al.
(2014) developed Monte-Carlo-based procedures to account
for multiplicity in the identification of genes that impact a
certain phenotype. These procedures allow arbitrary corre-
lations among the single nucleotide polymorphisms (SNPs)
across the whole genome and are shown to be substantially
more powerful than other existing methods. Unlike in GWAS
where there are high-dimensional covariates (i.e., SNPs), in
the drug safety analysis, we have high-dimensional outcomes
from different types of AEs while there is only one covari-
ate involved (i.e., the treatment indicator). In this paper, we
develop Monte-Carlo-based procedures for the detection of
drug safety signals which can account for both rare events and
multiplicity.
The rest of the paper is organized as follows. In Section 2,
we describe the Monte-Carlo procedure for signal detection.
Extensive simulation studies examining the finite-sample per-
formance of the proposed method are conducted in Section
3. Applications to two real examples are provided in Section
4. We conclude the paper with some discussions and future
research in Section 5.
2 METHODS
Suppose that there are 𝐵 BSs, with 𝑘𝑏 AE terms for BS 𝑏.
The 𝑗th type within BS 𝑏 is labeled as 𝐴𝑏𝑗 , 𝑏 = 1,… , 𝐵 and
𝑗 = 1,… , 𝑘𝑏. Suppose that there are 𝑛 independent subjects,
𝑛0 of which are in the control group and the remaining 𝑛1 =
𝑛 − 𝑛0 subjects are in the treatment group. For 𝑖 = 1,… , 𝑛,
we define 𝑋𝑖 as the treatment indicator taking value 0 for the
control group and 1 for the treatment group, and 𝑌𝑖𝑏𝑗 = 1 (𝑏 =
1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏) if subject 𝑖 experiences the 𝑗th type
AE in the 𝑏th BS and 0 otherwise. We assume that the time at
risk for all patients are the same although this assumption can
be relaxed; some discussions are provided in Section 5.
Our objective is to detect the AEs that have higher rates
in the treatment group than in the placebo group. Multiple
comparisons arise as there are 𝑀 =
∑𝐵
𝑏=1 𝑘𝑏 AE terms and
the occurrences of certain AE terms may be correlated. Stan-
dard methods may lead to inflated type I error rates without
appropriate multiple comparison adjustment. On the other
hand, Bonferroni correction is known to be conservative in
the presence of correlations.
We consider the following logistic regression model for
each AE:
log
𝑃 (𝑌𝑖𝑏𝑗 = 1|𝑋𝑖)
𝑃 (𝑌𝑖𝑏𝑗 = 0|𝑋𝑖) = 𝛼𝑏𝑗 + 𝛽𝑏𝑗𝑋𝑖, 𝑖 = 1,… , 𝑛;
𝑏 = 1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏.
To test the null hypothesis of 𝛽𝑏𝑗 = 0, we can use the stan-
dard likelihood ratio test, the Wald test, or the score test.
All three test statistics have the same asymptotic distribution.
Additionally, we can show that, under the null hypothesis, the
likelihood ratio test statistic can be represented in the form
𝑈2
𝑏𝑗
∕𝑉𝑏𝑗 + 𝑜𝑝(1), where 𝑈𝑏𝑗 =
∑𝑛






𝑈𝑖𝑏𝑗 = (𝑌𝑖𝑏𝑗 − 𝜋𝑏𝑗)(𝑋𝑖 − ?̄?), and ?̄? = 𝑛−1
∑𝑛
𝑖=1 𝑋𝑖. Here
𝜋𝑏𝑗 is the AE rate under the null hypothesis and can be esti-
mated by 𝜋𝑏𝑗 =
∑𝑛
𝑖=1 𝑌𝑖𝑏𝑗∕𝑛. Write 𝑊𝑏𝑗 = 𝑈𝑏𝑗∕
√
𝑉𝑏𝑗 . For
fixed 𝑏 and 𝑗, 𝑊𝑏𝑗 converges to a standard normal distribu-
tion under the null hypothesis. Furthermore, the correlation
between 𝑊𝑏𝑗 and 𝑊𝑏′𝑗′ can be consistently estimated by∑𝑛
𝑖=1 𝑈𝑖𝑏𝑗𝑈𝑖𝑏′𝑗′∕
√
𝑉𝑏𝑗𝑉𝑏′𝑗′ , where 𝑈𝑖𝑏𝑗 = (𝑌𝑖𝑏𝑗 − 𝜋𝑖𝑏𝑗)(𝑋𝑖 −





. It is worth to note that the above for-
mulation allows us to account for correlations among AEs not
only from the same BS but also from different BSs.
When the number of AE terms is small, we can estimate
the correlations of the test statistics and then draw samples
from the joint null distribution of the test statistics. However,
in most applications, 𝑀 is large and possibly greater than
sample size 𝑛. In this case, we can adopt the multiplier boot-
strap procedure using the Rademacher sequence as described
in Diao et al. (2014).
We now consider a sequence of i.i.d. random variables
𝐆 ≡ (𝐺1,… , 𝐺𝑛) independent of the data with 𝐸(𝐺1) = 0 and
Var(𝐺1) = 1. It can be shown that under the null hypothesis,











Therefore, given the observed data, the conditional joint
distribution of {𝑊𝑏𝑗(𝐆) ∶ 𝑏 = 1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏}
can be used to approximate the joint null distribu-






While it is challenging to derive the analytic form of the
joint distribution of the test statistics, based on the above
results, one can generate a large number of realizations
from the joint (conditional) distribution of {𝑊𝑏𝑗(𝐆) ∶ 𝑏 =
1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏} by generating a large number of ran-
dom sequences of (𝐺1,… , 𝐺𝑛). The subsequent inference is
based on these realizations.
Several choices of the distribution of 𝐺𝑖 are available; for
example, Diao et al. (2004) and Lin (2005) considered the
standard normal distribution. Empirical studies by Diao et al.
(2014) suggested that the choice of Rademacher sequence, in
which 𝑃 (𝐺𝑖 = 1) = 𝑃 (𝐺𝑖 = −1) = 1∕2, performs well espe-
cially when 𝑀 ≫ 𝑛. Furthermore, for a multiplier process
𝑛−1∕2
∑𝑛
𝑖=1 𝑍𝑖𝐺𝑖, where 𝑍𝑖’s are i.i.d. random variables and
𝑍𝑖 and 𝐺𝑖 are independent, a Rademacher sequence preserves
variance and other even moments and hence can lead to more
accurate higher order approximations. More discussions on
the properties of the Rademacher sequence can be found in
Koltchinskii (2006) and Tao (2009).
We describe the multiplier bootstrap procedure using the
Rademacher sequence to control for the FWER as follows:
1. For 𝑙 = 1,… , 𝐿, generate i.i.d. Rademacher random vari-
ables {𝐺(𝑙)1 ,… , 𝐺
(𝑙)
𝑛 }, which are independent of the data.



















3. For a given FWER 𝛼, compute the 1−𝛼 sample quantile of
{||𝐖(𝑙)||∞, 𝑙 = 1,… , 𝐿}, where ||𝐖(𝑙)||∞ = sup{𝑊 (𝑙)𝑏𝑗 ∶
𝑏 = 1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏}. Reject the null hypothesis if||𝐖||∞ exceeds this threshold, where 𝐖 = {𝑊𝑏𝑗 ∶ 𝑏 =
1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏}.
In step 3, we can also calculate (an estimate of) the
multiple testing adjusted 𝑝-value given as the proportion of
{||𝐖(𝑙)||∞ ∶ 𝑙 = 1,… , 𝐿} that are greater than or equal to||𝐖||∞. The standard error of the 𝑝-value estimate is bounded
from above by
√
𝑝(1 − 𝑝)∕𝐿 ≤ 1∕(2
√
𝐿), where 𝑝 is the true
(adjusted) 𝑝-value. Therefore, we can choose the value of 𝐿 to
control the standard error of the 𝑝-value estimate at a specified
level.
Remark 1. The proposed multiplier bootstrap procedure
accounts for arbitrary correlations among the test statistics at
AEs within the same BS or across different BSs.
Remark 2. Since the proposed multiplier bootstrap pro-
cedure is simulation-based, its performance does not rely on
the large sample approximations which require relatively large
sample sizes and event rates away from 0 and 1. Therefore this
procedure is applicable in the presence of rare events as shown
in the numerical studies.
3 SIMULATION STUDIES
We conduct extensive simulation studies to examine the per-
formance of the proposed procedure to control FWER. We
consider two simulation settings mimicking the two real
examples in Section 4: one from a vaccine trial (Example One)
and the other from an anti-depression trial (Example Two).
In the first simulation setting, there are eight BSs. The corre-
sponding numbers of AEs are 5, 7, 1, 1, 3, 11, 9, and 3. In
the second simulation setting, there are twenty-one BSs, with
1, 9, 1, 7, 1, 10, 43, 27, 2, 28, 13, 15, 4, 24, 47, 41, 10, 18,
19, 25, and 6 AE terms in BSs 1-21, respectively. We use the
observed proportion of event data for each AE in the com-
bined data to generate data for the control group. In Example
One, the observed proportion of event ranges from 0.008 to
0.490 with a median of 0.019 and a third quartile of 0.087. In
Example Two, the observed proportion of event ranges from
0.002 to 0.214 with a median of 0.002 and a third quartile of
0.006. In particular, for 206 AE terms, the event rate is less
than or equal to 0.002.
To generate correlated binary data, we first
generate a multivariate normal vector 𝐙 ≡
(𝑍11,… , 𝑍1𝑘1 ,… , 𝑍𝐵1,… , 𝑍𝐵𝑘𝐵 ) ∼ 𝑁(𝟎,𝚺), where 𝚺
is a variance-covariance matrix. All the diagonal elements of
𝚺 are equal to one. We then determine 𝐘 by
𝑌𝑏𝑗 =
{
1, if 𝑍𝑏𝑗 ≤ Φ−1(𝑝𝑏𝑗)
0, otherwise
,
where 𝑝𝑏𝑗 is the event rate for the 𝑗th AE in the 𝑏th BS, Φ(⋅)
is the cumulative distribution function of 𝑁(0, 1) and Φ−1(⋅)
is its inverse function.
We consider different values for the variance-covariance
matrix 𝚺. Specifically, we assume that 𝚺 depends on two
parameters: the correlation coefficient among AEs from the
same BS and the correlation coefficient among AEs across
different BSs. Specifically, we let
Cov(𝑍𝑏𝑗,𝑍𝑏′𝑘) =
{
𝜌, 𝑏 = 𝑏′, 𝑗 ≠ 𝑘
𝑟, 𝑏 ≠ 𝑏′
.
We consider seven different pairs of (𝜌, 𝑟):
(0, 0), (0.3, 0), (0.6, 0), (0.9, 0), (0.3, 0.15), (0.6, 0.3), and
(0.9, 0.45). For the first scenario, all AEs are mutually inde-
pendent. For scenarios 2–4, there are within-BS correlations
whereas AEs from different BSs are independent. For scenar-
ios 5–7, all AEs are correlated; however, AEs from the same
BS have higher correlations than AEs from different BSs.
We consider sample sizes of 50 and 100 in each treatment
group. All results are based on 1,000 replicates with 10,000
Rademacher sequences for each replicate.
We examine the performance of the proposed multiplier
bootstrap method using Rademacher sequences for control-
ling the FWER. For comparison, we also consider the Bon-
ferroni correction procedure and the permutation procedure
using the Fisher’s exact test and score-type test described in
Section 2. For Bonferroni correction procedures, we first cal-
culate the un-adjusted 𝑝-values and then compare them with
𝛼∕𝑀 , where 𝛼 is the nominal significance level and 𝑀 is the
previously-defined total number of AE terms across all BSs.
The permutation tests are based on 10,000 permuted samples.
All tests are one-sided testing whether the event rate is higher
in the treatment group than in the control group. We reject the
null hypothesis if at least one AE is detected.
Table 1 presents the type I error rates at the significance
level of 0.05 for simulation settings based on Example One
and Example Two. In all cases, both the proposed method and
the permutation methods have accurate control of the FWER,
whereas the Bonferroni correction yields conservative results,
especially with the Fisher’s exact test. As expected, the Bon-
ferroni correction is more conservative when the number of
AE terms is large. We also compare the computation complex-
ity of the proposed method with the permutation methods. On
average, the proposed test is about 5 times faster than the per-
mutation method using the score-type test and 6 times faster
than the permutation method using the Fisher’s exact test. One
would see even more computational advantage of the pro-
posed method over the permutation methods when analyzing
each permuted data set involves iterative procedures.
For the alternative hypothesis, we increase the event rate
by 0.1 for the first and twenty first AEs in the treatment group.
The event rates at these two AE terms for settings based on
Example One are 0.402 and 0.087 in the control group. The
corresponding relative risks at these two AE terms are 1.248
and 2.148. For settings based on Example Two, both event
rates at these two AE terms are 0.002 in the control group lead-
ing to relative risks of 47.8. Table 2 presents the powers at the
significance level of 0.05. Table 3 presents the corresponding
TABLE 1 Type I error rates for detecting at least one AE at the nominal significance level of 0.05 based on 1,000 replicates.
𝑛 𝜌 𝑟 Bonf. (Fisher) Bonf. (Score) Perm. (Fisher) Perm. (Score) Proposed
Simulation settings mimicking Example One
100 0 0 0.006 0.017 0.058 0.055 0.060
0.3 0 0.002 0.017 0.048 0.047 0.050
0.6 0 0.004 0.014 0.045 0.047 0.045
0.9 0 0.004 0.012 0.042 0.039 0.043
0.3 0.15 0.004 0.015 0.05 0.048 0.050
0.6 0.3 < 0.001 0.008 0.044 0.048 0.046
0.9 0.45 0.001 0.008 0.026 0.028 0.030
200 0 0 0.003 0.019 0.051 0.056 0.051
0.3 0 0.007 0.019 0.040 0.047 0.042
0.6 0 0.004 0.021 0.047 0.047 0.045
0.9 0 0.006 0.013 0.037 0.037 0.036
0.3 0.15 0.011 0.020 0.049 0.052 0.052
0.6 0.3 0.009 0.021 0.053 0.056 0.054
0.9 0.45 0.005 0.016 0.052 0.058 0.053
Simulation settings mimicking Example Two
100 0 0 < 0.001 0.003 0.049 0.044 0.056
0.3 0 < 0.001 0.001 0.042 0.042 0.052
0.6 0 < 0.001 0.001 0.054 0.055 0.066
0.9 0 < 0.001 0.001 0.049 0.049 0.049
0.3 0.15 0.001 0.001 0.041 0.046 0.047
0.6 0.3 < 0.001 < 0.001 0.042 0.048 0.056
0.9 0.45 < 0.001 < 0.001 0.048 0.047 0.049
200 0 0 0.001 0.002 0.054 0.062 0.062
0.3 0 0.001 0.003 0.044 0.052 0.046
0.6 0 0.002 0.004 0.053 0.061 0.059
0.9 0 < 0.001 0.002 0.044 0.050 0.044
0.3 0.15 < 0.001 0.002 0.043 0.050 0.046
0.6 0.3 < 0.001 0.002 0.045 0.055 0.054
0.9 0.45 0.001 0.002 0.031 0.039 0.036
sensitivities for the tests. Here sensitivity is defined as the pro-
portion of correct decisions for the two true signals. For the
permutation methods and the proposed method, sensitivity is∑𝑁
𝑗=1{𝐼(𝑝𝑗,1 < 0.05) + 𝐼(𝑝𝑗,21 < 0.05)}∕(2𝑁), where 𝑝𝑗,𝑘 is
the estimated adjusted 𝑝-value for the 𝑘th AE from the 𝑗th
replicate, respectively, and 𝑁 is the total number of replicates.
For the methods using the Bonferroni correction, sensitiv-
ity is
∑𝑁
𝑗=1{𝐼(𝑝𝑗,1 < 0.05∕𝑀) + 𝐼(𝑝𝑗,21 < 0.05∕𝑀)}∕(2𝑁),
where 𝑝𝑗,𝑘 is the un-adjusted 𝑝-value for the 𝑘th AE from the
𝑗th replicate. As expected, the Bonferroni correction methods
perform very poorly with very low powers and sensitivities
especially when the number of AEs is large. For settings mim-
icking Example One, the performance of the proposed test and
the permutation tests are comparable; however, the proposed
multiplier method is much more powerful than its permutation
counterparts under the simulation setting mimicking Exam-
ple Two with sample size 𝑛 = 100, in which there are a large
number of AEs with rare events. These results suggest that the
permutation tests may lose power compared to the proposed
method when there are rare events and sample size is small.
The powers/sensitivities appear to be low under some simu-
lation settings due to either small sample sizes or small effect
sizes. As the sample size or effect size increases, we achieve
better powers/sensitivities.
For every method under consideration, we also calculated
the specificity, which is defined as the proportion of correct
decisions for the 𝑀 − 2 AEs such that the null hypothesis is
true. For the permutation methods and the proposed method,





0.05)∕{(𝑀 − 2)𝑁)}; for the methods using the
Bonferroni correction, specificity is defined as∑𝑁
𝑗=1
∑
1≤𝑘≤𝑀,𝑘≠1,𝑘≠21 𝐼(𝑝𝑗,𝑘 ≥ 0.05∕𝑀)∕{(𝑀 − 2)𝑁)}. In
all simulation settings, the specificities for every method are
greater than 0.999 suggesting low false positive rates.
We conduct additional simulation studies under different
settings of the correlation structure of the AE terms. The
results are presented in Web Appendix B. The conclusions
from the new simulations remain the same.
4 APPLICATION
We apply the proposed method to two real clinical trials. In
both examples, we generated 100,000 Rademacher sequences
TABLE 2 Powers for detecting at least one AE at the nominal significance level of 0.05 based on 1,000 replicates.
𝑛 𝜌 𝑟 Bonf. (Fisher) Bonf. (Score) Perm. (Fisher) Perm. (Score) Proposed
Simulation settings mimicking Example One
100 0 0 0.034 0.091 0.200 0.201 0.211
0.3 0 0.036 0.094 0.189 0.178 0.190
0.6 0 0.032 0.072 0.183 0.190 0.190
0.9 0 0.035 0.076 0.183 0.181 0.190
0.3 0.15 0.029 0.077 0.186 0.188 0.193
0.6 0.3 0.029 0.070 0.177 0.179 0.180
0.9 0.45 0.028 0.072 0.161 0.147 0.152
200 0 0 0.161 0.229 0.384 0.378 0.379
0.3 0 0.159 0.221 0.372 0.363 0.358
0.6 0 0.140 0.217 0.372 0.359 0.361
0.9 0 0.151 0.198 0.344 0.340 0.337
0.3 0.15 0.147 0.219 0.374 0.366 0.364
0.6 0.3 0.151 0.215 0.364 0.353 0.350
0.9 0.45 0.159 0.221 0.360 0.354 0.356
Simulation settings mimicking Example Two
100 0 0 0.009 0.055 0.450 0.465 0.577
0.3 0 0.006 0.043 0.459 0.477 0.592
0.6 0 0.007 0.047 0.458 0.480 0.592
0.9 0 0.006 0.048 0.500 0.541 0.633
0.3 0.15 0.006 0.054 0.457 0.484 0.589
0.6 0.3 0.009 0.049 0.458 0.486 0.575
0.9 0.45 0.007 0.041 0.503 0.561 0.614
200 0 0 0.327 0.631 0.947 0.981 0.973
0.3 0 0.320 0.608 0.946 0.978 0.972
0.6 0 0.322 0.613 0.958 0.978 0.972
0.9 0 0.353 0.615 0.966 0.984 0.980
0.3 0.15 0.330 0.597 0.948 0.975 0.967
0.6 0.3 0.326 0.593 0.940 0.964 0.958
0.9 0.45 0.310 0.576 0.953 0.970 0.970
for the proposed method and 100,000 permuted samples for
the permutation methods.
4.1 Example one: safety analysis for a
vaccine trial
We first illustrate the proposed method using the safety data
collected from a vaccine trial. The data were published by
Mehrotra and Heyse (2004a). The trial randomized healthy
toddlers aged 12–18 months into a quadrivalent vaccine
containing measles, mumps, rubella, and varicella (MMRV)
administrated on day 0, or a tri-valent vaccine containing
measles, mumps and rubella (MMR) administrated on day
0 followed by varicella (V) on day 42. The primary safety
comparison was between the combination vaccine MMRV
and the separate administration of varicella (control group),
i.e., adverse experiences observed in the MMRV group during
days 0–42 and that observed following the varicella vaccina-
tion (days 42–84). A total of 280 subjects were included in
the data set (148 in the MMRV group, and 132 in the control
group). Overall, there were 40 different AE terms involving 8
BSs.
Figures 3(a) and 3(b) in Web Appendix C present the
heat maps of Spearman’s correlation matrices of the raw
outcome data and the proposed test statistics across the 40
AEs, respectively. It appears that the proposed method can
capture the correlations across all AEs well. By using the pro-
posed method, the adjusted 𝑝-value is 0.834 at the AE with
the smallest 𝑝-value. Similar results were obtained from the
permutation methods. The adjusted 𝑝-values are 0.855 and
0.767, respectively, corresponding to the permutation meth-
ods with the Fisher’s exact test and the score-type test. Figure
3(c) in Web Appendix C displays the adjusted 𝑝-values and
no significant signals were detected using either of the three
methods.
4.2 Example two: safety analysis for an
anti-depression trial
We now apply the proposed method to an anti-depression clin-
ical trial for substance-p antagonist aprepitant (Keller et al.,
2006). In this trial, 468 patients aged 18 years or older with a
documented diagnosis of major depression disorder were ran-
domized in approximately equal ratios to receive aprepitant
TABLE 3 Sensitivity based on 1,000 replicates.
𝑛 𝜌 𝑟 Bonf. (Fisher) Bonf. (Score) Perm. (Fisher) Perm. (Score) Proposed
Simulation settings mimicking Example One
100 0 0 0.014 0.038 0.080 0.080 0.084
0.3 0 0.017 0.040 0.081 0.076 0.082
0.6 0 0.014 0.031 0.079 0.082 0.082
0.9 0 0.016 0.034 0.084 0.083 0.086
0.3 0.15 0.012 0.033 0.080 0.080 0.083
0.6 0.3 0.014 0.034 0.081 0.080 0.083
0.9 0.45 0.014 0.036 0.084 0.077 0.080
200 0 0 0.082 0.114 0.194 0.188 0.192
0.3 0 0.078 0.109 0.194 0.185 0.184
0.6 0 0.069 0.103 0.188 0.181 0.182
0.9 0 0.074 0.098 0.178 0.173 0.172
0.3 0.15 0.073 0.110 0.198 0.190 0.190
0.6 0.3 0.076 0.110 0.193 0.187 0.185
0.9 0.45 0.080 0.113 0.198 0.194 0.194
Simulation settings mimicking Example Two
100 0 0 0.004 0.026 0.242 0.256 0.330
0.3 0 0.003 0.021 0.249 0.264 0.340
0.6 0 0.004 0.023 0.248 0.264 0.351
0.9 0 0.003 0.024 0.272 0.306 0.376
0.3 0.15 0.002 0.026 0.254 0.270 0.347
0.6 0.3 0.004 0.024 0.259 0.278 0.347
0.9 0.45 0.004 0.020 0.294 0.337 0.384
200 0 0 0.179 0.390 0.776 0.844 0.827
0.3 0 0.175 0.372 0.766 0.839 0.819
0.6 0 0.178 0.374 0.774 0.829 0.814
0.9 0 0.194 0.382 0.784 0.840 0.828
0.3 0.15 0.182 0.370 0.775 0.839 0.826
0.6 0.3 0.187 0.376 0.778 0.830 0.816
0.9 0.45 0.178 0.372 0.807 0.844 0.838
160 mg, paroxetine HCl 20 mg, or placebo for a period of 8
weeks. Adverse experiences that occurred during this treat-
ment period were included in the primary safety analysis for
the comparisons. In the data set, 220 patients were in the test
treatment group and 248 patients were in the control group.
Of the 468 patients in the study, 364 patients reported at least
one AEs. A total of 351 different AE teams were reported in
21 BSs. In this data set, for many AE terms, the number of
observed events is very small. In the placebo arm, no patients
experienced any event for 133 AE terms and only one event
was observed for 146 AE terms; in the treatment arm, there
were no observed events for 114 AE terms and there was only
one observed event for 145 AE terms.
Figures 5(a) and 5(b) in Web Appendix C present the
heat maps of Spearman’s correlation matrices of the raw
outcome data and the proposed test statistics across the 351
AEs, respectively. It appears that most AEs are independent.
The proposed method was able to capture those AE pairs
with noticeable correlations. All three methods detected the
same signals at at AE #42 Dry mouth and AE #59 Nausea.
The adjusted 𝑝-values were 0.017, 0.015, 0.013 for AE #42,
and 0.031, 0.020, 0.020 for AE #59, corresponding to the
proposed method, the permutation methods with the Fisher’s
exact test and the score-type test, respectively. Figure 5(c)
in Web Appendix C displays the adjusted 𝑝-values. On the
other hand, no tests using the Bonferroni correction detect
any signals.
5 DISCUSSION
This paper proposes an efficient method for drug safety signal
detection from correlated AEs in clinical trials. The advan-
tages of the proposed multiplier bootstrap method for con-
trolling the FWER are twofold. First, the proposed method
allows for arbitrary correlation structures of the test statis-
tics within the same BS and across different BSs. Second, the
proposed method is simulation-based and thus less sensitive
to rare events than methods relying on large sample theories.
Additionally, compared to the permutation method, the pro-
posed method is computationally more efficient and appears to
have superior power to detect the true signals with rare events
and small samples based on empirical studies.
We have considered binary outcomes whether a sub-
ject experiences an AE from a certain BS. An underlying
assumption is that all patients have the same exposure time.
Furthermore, patients with multiple occurrences of an AE are
treated the same as patients who experience the AE only once.
In many studies, patients may have different exposure times to
the treatment and they may experience an AE multiple times.
Failing to account for varying exposure times or utilize all the
available information may result in loss of statistical power
for detecting AE signals. As a future topic, we will consider
several regression models including the Poisson model, the
negative binomial model, and zero-inflated models and then
apply the proposed Monte-Carlo method for multiple testing
adjustment.
It is possible that the adverse reaction to a drug is impacted
by some factors such as age, gender, ethnicity, etc. To account
for the confounding effects of these factors, one may include
them as covariates in a regression model. Following Diao
et al. (2014), we can derive the efficient influence function
for the parameter of interest, i.e., the treatment effect and
then apply the proposed multiplier bootstrap method using
Rademacher sequences. Since iterative procedures are needed
to analyze each permuted data set, the permutation method
can be computationally very intensive. On the other hand, the
proposed multiplier bootstrap method only involves the anal-
ysis once for each AE and therefore is computationally much
more efficient than the permutation method.
Recently, Segal et al. (2018) proposed an asymptotic
approximation and a resampling algorithm for quickly esti-
mating small permutation 𝑝-values in two-sample tests. The
authors showed that their proposed algorithm is more compu-
tationally efficient than standard alternatives, particularly for
extremely small 𝑝-values. In our application, due to the nature
of rare events and small to moderate large sample sizes, in
general the 𝑝-values are not small. It would be interesting to
apply this method to our setting in a future research project.
The proposed method is developed for drug safety data
from clinical trials in which the individual-level data are avail-
able and there are two treatment groups. In some clinical
trials, there are more than two treatment groups or multiple
dose levels. The proposed method can be extended to incor-
porate such scenarios. Suppose that there are 𝐾 + 1 treatment
groups including the control group. The variable 𝑋𝑖 takes
value 0 for the control group and value 𝑘 for the 𝑘th treat-
ment or dose level, 𝑘 = 1,… , 𝐾 . We consider the following
logistic regression model for each AE with the control group
as the reference level:
log
𝑃 (𝑌𝑖𝑏𝑗 = 1|𝑋𝑖)




𝑖 = 1,… , 𝑛; 𝑏 = 1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏,
where 𝐼(⋅) is the indicator function. We are interested in test-
ing the null hypotheses 𝛽𝑏𝑗1 = ⋯ = 𝛽𝑏𝑗𝐾 = 0 for all 𝑏 =
1,… , 𝐵 and 𝑗 = 1,… , 𝑘𝑏. The efficient score for 𝛽𝑏𝑗𝑘 for the
𝑖th subject is then 𝑈𝑖𝑏𝑗𝑘 = (𝑌𝑖𝑏𝑗 − 𝜋𝑏𝑗){𝐼(𝑋𝑖 = 𝑘) − 𝑛𝑘∕𝑛},
where 𝜋𝑏𝑗 is the AE rate under the null hypothesis, and 𝑛𝑘 =∑𝑛
𝑖=1 𝐼(𝑋𝑖 = 𝑘) is the number of patients in the 𝑘th treatment








, and 𝑊𝑏𝑗 = 𝐔𝑇𝑏𝑗𝐕
−1
𝑏𝑗
𝐔𝑏𝑗 . For fixed 𝑏 and
𝑗, 𝑊𝑏𝑗 converges to a chi-square distribution with degrees of
freedom 𝐾 under the null hypothesis. Replacing the unknown
parameter 𝜋𝑏𝑗 with its estimator under the null hypothesis 𝜋𝑏𝑗 ,
we obtain 𝑈𝑖𝑏𝑗𝑘, ?̃?𝑖𝑏𝑗 , ?̃?𝑏𝑗 , ?̃?𝑏𝑗 , and 𝑊𝑏𝑗 . Following Section








𝑖=1 ?̃?𝑖𝑏𝑗𝐺𝑖} also converges to a chi-
square distribution with degrees of freedom 𝐾 for a sequences
of Rademacher random variables 𝐺𝑖, 𝑖 = 1,… , 𝑛. Further-
more, it can be shown that {𝑊𝑏𝑗, 𝑏 = 1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏}
and {𝑊𝑏𝑗, 𝑏 = 1,… , 𝐵; 𝑗 = 1,… , 𝑘𝑏} (given the observed
data) have the same limiting joint distribution. The same mul-
tiplier bootstrap procedure described in Section 2 then can be
used to control for the FWER.
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